Tegaserod (Zelnorm) safety profile in pediatric patients

被引：0
|
作者：
Har, Aileen F. [1 ]
Steffen, Rita [1 ]
Kaplan, Barbara [1 ]
Mahajan, Lori [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2007年 / 102卷
关键词：
D O I：
10.14309/00000434-200709002-01041
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1041
引用
收藏
页码：S500 / S500
页数：1
相关论文
共 50 条
  • [31] Clinical Effectiveness, Safety Profile, and Pharmacokinetics of Daptomycin in Pediatric Patients: A Systematic Review
    Karageorgos, Spyridon A.
    Miligkos, Michael
    Dakoutrou, Maria
    Tsioutis, Constantinos
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2016, 5 (04) : 446 - 457
  • [32] Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
    Sadowski, Krzysztof
    Sijko, Kamil
    Domanska-Pakiela, Dorota
    Borkowska, Julita
    Chmielewski, Dariusz
    Ulatowska, Agata
    Jozwiak, Sergiusz
    Kotulska, Katarzyna
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [33] Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation
    Mueller-Lissner, Stefan
    Kamm, Michael A.
    Musoglu, Ahmet
    Earnest, David L.
    Dunger-Baldauf, Cornelia
    Shetzline, Michael A.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (11): : 2558 - 2569
  • [34] SAFETY AND EFFICACY OF TEGASEROD THERAPY IN PATIENTS WITH IRRITABLE BOWEL SYNDROME OR CHRONIC CONSTIPATION
    Al-Judaibi, B.
    Chande, N.
    Gregor, J. C.
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2010, 17 (01): : E194 - E200
  • [35] Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia. (vol 170, pg 1908, 2004)
    Wooltorton, E
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (07) : 712 - 712
  • [36] Safety profile of tegaserod, a 5-HT4 receptor agonist, for the treatment of irritable bowel syndrome
    Hasler, WL
    Schoenfeld, P
    DRUG SAFETY, 2004, 27 (09) : 619 - 631
  • [37] Safety Profile of Tegaserod, a 5-HT4 Receptor Agonist, for the Treatment of Irritable Bowel Syndrome
    William L. Hasler
    Philip Schoenfeld
    Drug Safety, 2004, 27 : 619 - 631
  • [38] ZAQ (Zelnorm advancing quality of life) study outcomes. Treatment with tegaserod in a naturalistic setting is associated with reductions in presenteeism and absenteeism
    Flook, N
    Choueri, G
    Kelly, S
    Barbeau, M
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (09): : S285 - S285
  • [39] The Effect of Direct to Consumer Advertisement and Physician Promotion of Tegaserod (Zelnorm) On Physician Visits, Diagnoses, and Prescriptions for Irritable Bowel Syndrome and Constipation
    Dorn, Spencer D.
    Farley, Joel E.
    Hansen, Richard A.
    Shah, Nilay
    Sandler, Robert S.
    GASTROENTEROLOGY, 2009, 136 (05) : A29 - A29
  • [40] Safety profile of quinolone antibiotics in the pediatric population
    Grady, R
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (12) : 1128 - 1132
12345